These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 29125591)

  • 61. Experience with biologics for psoriasis in daily practice: switching is worth a try.
    Lecluse LL; de Groot M; Bos JD; Spuls PI
    Br J Dermatol; 2009 Oct; 161(4):948-51. PubMed ID: 19663876
    [No Abstract]   [Full Text] [Related]  

  • 62. [Treatment of severe psoriasis with anti-TNF-alpha-antibody and methotrexate].
    Dalaker M; Bonesrønning JH
    Tidsskr Nor Laegeforen; 2003 Apr; 123(8):1070-1. PubMed ID: 12760225
    [No Abstract]   [Full Text] [Related]  

  • 63. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
    Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H
    Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Treatment of inverse psoriasis with efalizumab.
    George D; Rosen T
    J Drugs Dermatol; 2009 Jan; 8(1):74-6. PubMed ID: 19180901
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Immunotherapy against psoriasis].
    Gjersvik PJ
    Tidsskr Nor Laegeforen; 2003 Apr; 123(8):1049. PubMed ID: 12760217
    [No Abstract]   [Full Text] [Related]  

  • 66. [Neurological symptoms following infusion of infliximab].
    Bebe AC; Harboe KM; Nøjgaard C
    Ugeskr Laeger; 2012 Oct; 174(40):2388-90. PubMed ID: 23031302
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
    Sofen H; Smith S; Matheson RT; Leonardi CL; Calderon C; Brodmerkel C; Li K; Campbell K; Marciniak SJ; Wasfi Y; Wang Y; Szapary P; Krueger JG
    J Allergy Clin Immunol; 2014 Apr; 133(4):1032-40. PubMed ID: 24679469
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical experience of secukinumab in the treatment of erythrodermic psoriasis: a case series.
    Weng HJ; Wang TS; Tsai TF
    Br J Dermatol; 2018 Jun; 178(6):1439-1440. PubMed ID: 29265175
    [No Abstract]   [Full Text] [Related]  

  • 69. Management of moderate to severe plaque psoriasis (part 2): clinical update on T-cell modulators and investigational agents.
    Sobell JM; Kalb RE; Weinberg JM
    J Drugs Dermatol; 2009 Mar; 8(3):230-8. PubMed ID: 19271369
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Misunderstandings.
    Feldman SR
    J Dermatolog Treat; 2007; 18(1):4. PubMed ID: 17365258
    [No Abstract]   [Full Text] [Related]  

  • 71. [Infliximab: patients selection].
    Puig L
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():23-9. PubMed ID: 19080988
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab.
    Bartke U; Venten I; Kreuter A; Gubbay S; Altmeyer P; Brockmeyer NH
    Br J Dermatol; 2004 Apr; 150(4):784-6. PubMed ID: 15099388
    [No Abstract]   [Full Text] [Related]  

  • 73. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
    Gordon KB; Papp KA; Hamilton TK; Walicke PA; Dummer W; Li N; Bresnahan BW; Menter A;
    JAMA; 2003 Dec; 290(23):3073-80. PubMed ID: 14679270
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.
    Menter A; Hamilton TK; Toth DP; Leung HM; Wetherill G; Hennessey B; Garovoy M; Kwon P; Pariser DM;
    Int J Dermatol; 2007 Jun; 46(6):637-48. PubMed ID: 17550570
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis.
    Heikkilä H; Ranki A; Cajanus S; Karvonen SL
    Arch Dermatol; 2005 Dec; 141(12):1607-10. PubMed ID: 16365275
    [No Abstract]   [Full Text] [Related]  

  • 76. Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefacept.
    Weinberg JM; Saini R; Tutrone WD
    J Drugs Dermatol; 2002 Dec; 1(3):303-10. PubMed ID: 12851990
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Secukinumab: a review in moderate to severe plaque psoriasis.
    Garnock-Jones KP
    Am J Clin Dermatol; 2015 Aug; 16(4):323-330. PubMed ID: 26202871
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Brodalumab: A Review of Safety.
    Rusta-Sallehy S; Gooderham M; Papp K
    Skin Therapy Lett; 2018 Mar; 23(2):1-3. PubMed ID: 29562088
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Ustekinumab.
    Weber J; Keam SJ
    BioDrugs; 2009; 23(1):53-61. PubMed ID: 19344192
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis.
    Takahashi MD; Castro LG; Romiti R
    Br J Dermatol; 2007 Oct; 157(4):828-31. PubMed ID: 17711530
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.